MY182327A - Sugar moiety silyl ether derivative of 5-azacytidine - Google Patents
Sugar moiety silyl ether derivative of 5-azacytidineInfo
- Publication number
- MY182327A MY182327A MYPI2018701923A MYPI2018701923A MY182327A MY 182327 A MY182327 A MY 182327A MY PI2018701923 A MYPI2018701923 A MY PI2018701923A MY PI2018701923 A MYPI2018701923 A MY PI2018701923A MY 182327 A MY182327 A MY 182327A
- Authority
- MY
- Malaysia
- Prior art keywords
- azacytidine
- formula
- substituent
- hydrogen atom
- sugar moiety
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016085145 | 2016-04-21 | ||
| PCT/JP2016/065660 WO2017183215A1 (ja) | 2016-04-21 | 2016-05-27 | ５－アザシチジン類の糖部シリルエーテル誘導体 |
| PCT/JP2016/072010 WO2017183217A1 (ja) | 2016-04-21 | 2016-07-27 | ５－アザシチジン類の糖部シリルエーテル誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY182327A true MY182327A (en) | 2021-01-19 |
Family
ID=60115962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018701923A MY182327A (en) | 2016-04-21 | 2016-07-27 | Sugar moiety silyl ether derivative of 5-azacytidine |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9901641B2 (enExample) |
| EP (2) | EP3543249A1 (enExample) |
| JP (2) | JP6162349B1 (enExample) |
| KR (1) | KR102579485B1 (enExample) |
| CN (1) | CN108368148B (enExample) |
| MY (1) | MY182327A (enExample) |
| WO (2) | WO2017183215A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10227374B2 (en) * | 2016-04-21 | 2019-03-12 | Ohara Pharmaceutical Co., Ltd. | Silyl etherified derivatives of 5-azacytidines in carbohydrate moiety |
| WO2019160127A1 (ja) * | 2018-02-19 | 2019-08-22 | 大原薬品工業株式会社 | Ｄｎｍｔ阻害剤の用途 |
| CN112638422B (zh) * | 2018-10-30 | 2023-03-17 | 大原药品工业株式会社 | 医药组合物 |
| JPWO2021060341A1 (enExample) * | 2019-09-26 | 2021-04-01 | ||
| WO2022031759A1 (en) * | 2020-08-04 | 2022-02-10 | Herophilus, Inc. | Decitabine induced mecp2 expression and uses thereof |
| CN116940365A (zh) * | 2021-02-23 | 2023-10-24 | 大原药品工业株式会社 | 慢性髓性白血病干细胞抑制剂 |
| WO2025142803A1 (ja) * | 2023-12-25 | 2025-07-03 | 大原薬品工業株式会社 | Ｄｎｍｔ阻害剤の経口投与用の医薬組成物 |
| WO2025263591A1 (ja) * | 2024-06-21 | 2025-12-26 | 大原薬品工業株式会社 | 経口用ｄｎｍｔ阻害剤の結晶形態 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3816619A (en) | 1965-08-25 | 1974-06-11 | Upjohn Co | Ladakamycin and process for preparing same |
| CH527207A (de) | 1968-05-08 | 1972-08-31 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen |
| DE2012888C3 (de) * | 1970-03-14 | 1981-04-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden |
| GB0227906D0 (en) * | 2002-11-29 | 2003-01-08 | Amedis Pharm Ltd | Compounds and their use |
| AU2003302624A1 (en) * | 2002-11-29 | 2004-06-23 | Amedis Pharmaceuticals Ltd. | Silicon compounds |
| KR100866399B1 (ko) | 2002-12-10 | 2008-11-03 | 엘지엔시스(주) | 매체자동지급기의 모듈부 스톱퍼장치 |
| KR100897924B1 (ko) | 2002-12-10 | 2009-05-18 | 엘지엔시스(주) | 금융통합단말기 프린터부의 용지가이드 장치 |
| US7700567B2 (en) * | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| CN102010455B (zh) * | 2009-09-05 | 2012-07-11 | 山东新时代药业有限公司 | 一种地西他滨的制备方法 |
| CN103619864A (zh) * | 2011-03-31 | 2014-03-05 | 细胞基因国际有限公司 | 5-氮杂胞苷的合成 |
| WO2013036846A2 (en) * | 2011-09-09 | 2013-03-14 | Koronis Pharmaceuticals, Incorporated | N4 derivatives of deoxycytidine prodrugs |
| WO2016057828A1 (en) * | 2014-10-08 | 2016-04-14 | Epigenetics Pharma Llc | Silylated pyrimidine prodrugs and methods of their use |
| KR101922702B1 (ko) | 2016-05-10 | 2018-11-29 | 주식회사 씨엔제이 | 기판용 필름의 재활용 칩 제작방법 및 장치 |
-
2016
- 2016-05-27 WO PCT/JP2016/065660 patent/WO2017183215A1/ja not_active Ceased
- 2016-07-27 CN CN201680072731.4A patent/CN108368148B/zh active Active
- 2016-07-27 JP JP2016565699A patent/JP6162349B1/ja active Active
- 2016-07-27 MY MYPI2018701923A patent/MY182327A/en unknown
- 2016-07-27 EP EP19160835.5A patent/EP3543249A1/en not_active Withdrawn
- 2016-07-27 WO PCT/JP2016/072010 patent/WO2017183217A1/ja not_active Ceased
- 2016-07-27 KR KR1020187018429A patent/KR102579485B1/ko active Active
- 2016-07-27 EP EP16797711.5A patent/EP3252067B1/en active Active
- 2016-11-18 US US15/355,315 patent/US9901641B2/en active Active
-
2017
- 2017-05-08 JP JP2017092160A patent/JP2017197539A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6162349B1 (ja) | 2017-07-12 |
| WO2017183217A1 (ja) | 2017-10-26 |
| JP2017197539A (ja) | 2017-11-02 |
| CN108368148A (zh) | 2018-08-03 |
| WO2017183215A1 (ja) | 2017-10-26 |
| EP3252067B1 (en) | 2019-05-29 |
| EP3252067A1 (en) | 2017-12-06 |
| EP3252067A4 (en) | 2017-12-06 |
| EP3543249A1 (en) | 2019-09-25 |
| CN108368148B (zh) | 2021-11-05 |
| KR20180134835A (ko) | 2018-12-19 |
| US20170304337A1 (en) | 2017-10-26 |
| JPWO2017183217A1 (ja) | 2018-04-26 |
| US9901641B2 (en) | 2018-02-27 |
| KR102579485B1 (ko) | 2023-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY182327A (en) | Sugar moiety silyl ether derivative of 5-azacytidine | |
| CY1124117T1 (el) | Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων | |
| MY210086A (en) | Pharmaceutical compounds | |
| JOP20180120A1 (ar) | مشتقات بيريدين مستبدلة كمثبطات انتقائية لـ dnmt1 | |
| CY1118572T1 (el) | Παραγωγο κυκλοαλκανιου | |
| MX2010006421A (es) | Compuestos organicos. | |
| UA95976C2 (en) | 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | |
| AU2018243463A8 (en) | 11,13-modified saxitoxins for the treatment of pain | |
| MX2016006919A (es) | Nucleotidos para el tratamiento de cancer de higado. | |
| PH12014501134B1 (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| PH12014501719A1 (en) | Pyridone derivatives | |
| MX2010009922A (es) | Activadores de piridazinona glucocinasa. | |
| MY150059A (en) | Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors | |
| MX2012013274A (es) | Novedosos derivados de la pirimidina. | |
| IL204437A (en) | History of aryl cyclic profile and their use | |
| TN2012000608A1 (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| NZ601483A (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12014501283A1 (en) | 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
| EP4582424A3 (en) | 1,2-naphthoquinone derivative and method for preparing same | |
| CA2920410C (en) | Thienopiperidine derivative and use thereof | |
| BR112018007128A2 (pt) | compostos para a inibição de câncer e epigênese | |
| PH12015500111A1 (en) | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions | |
| JP2014519507A5 (enExample) | ||
| HK1217295A1 (zh) | 4'-疊氮基，3'-脫氧基-3'-氟取代的核苷衍生物 |